Tower Research Capital LLC (TRC) - BIOCRYST PHARMACEUTICALS INC ownership

BIOCRYST PHARMACEUTICALS INC's ticker is BCRX and the CUSIP is 09058V103. A total of 3 filers reported holding BIOCRYST PHARMACEUTICALS INC in Q4 2023. The put-call ratio across all filers is - and the average weighting 0.1%.

Quarter-by-quarter ownership
Tower Research Capital LLC (TRC) ownership history of BIOCRYST PHARMACEUTICALS INC
ValueSharesWeighting
Q3 2023$31,916
-80.7%
4,508
-80.8%
0.00%
-83.3%
Q2 2023$165,594
+168873.5%
23,522
+99.4%
0.01%
+100.0%
Q1 2023$98
-47.3%
11,799
-27.3%
0.00%
-62.5%
Q4 2022$186
-100.0%
16,226
-65.3%
0.01%
-20.0%
Q3 2022$589,000
+55.0%
46,713
+30.3%
0.01%
+11.1%
Q2 2022$380,000
+44.5%
35,861
+121.6%
0.01%
+200.0%
Q1 2022$263,000
-23.5%
16,180
-34.8%
0.00%
-50.0%
Q4 2021$344,000
-38.5%
24,829
-36.1%
0.01%
-57.1%
Q3 2021$559,000
+81.5%
38,885
+99.7%
0.01%
+75.0%
Q2 2021$308,000
-50.5%
19,472
-68.1%
0.01%
-20.0%
Q1 2021$622,000
+30.9%
61,104
-4.3%
0.01%
-33.3%
Q4 2020$475,000
-68.8%
63,838
-85.6%
0.02%
-11.8%
Q3 2020$1,524,000
+218.2%
443,635
+341.5%
0.02%
-15.0%
Q2 2020$479,000
+15866.7%
100,491
+28367.7%
0.02%
Q1 2019$3,000
+200.0%
353
+16.1%
0.00%
Q4 2017$1,000
-98.0%
304
-96.8%
0.00%
-100.0%
Q3 2017$50,000
+1566.7%
9,439
+1473.2%
0.00%
Q2 2017$3,000
-93.3%
600
-91.7%
0.00%
-100.0%
Q4 2016$45,000
+2150.0%
7,239
+1512.2%
0.01%
Q3 2016$2,000
-71.4%
449
-81.4%
0.00%
-100.0%
Q2 2016$7,000
-84.1%
2,417
-43.0%
0.00%
-85.7%
Q4 2015$44,000
-37.1%
4,237
-9.3%
0.01%
+16.7%
Q2 2015$70,000
-1.4%
4,673
-40.1%
0.01%
-33.3%
Q1 2015$71,000
+129.0%
7,802
+202.3%
0.01%
+200.0%
Q4 2014$31,000
+72.2%
2,581
+40.3%
0.00%
+50.0%
Q3 2014$18,000
-91.3%
1,839
-88.6%
0.00%
-92.6%
Q2 2014$207,000
+1492.3%
16,161
+1211.8%
0.03%
+1250.0%
Q1 2014$13,000
+116.7%
1,232
+60.4%
0.00%
+100.0%
Q4 2013$6,000
-94.7%
768
-95.1%
0.00%
-91.7%
Q3 2013$114,000
+533.3%
15,628
+34.9%
0.01%
+1100.0%
Q2 2013$18,00011,5820.00%
Other shareholders
BIOCRYST PHARMACEUTICALS INC shareholders Q4 2023
NameSharesValueWeighting ↓
VHCP Management, LLC 1,744,356$18,455,0009.59%
RA Capital Management 4,347,456$45,996,0003.30%
Cormorant Asset Management, LP 1,168,000$12,357,0002.84%
Baker Brothers Advisors 5,867,031$62,073,0000.79%
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) 907,920$9,606,0000.39%
QVT Financial LP 525,734$5,562,0000.32%
EAM Investors, LLC 114,548$1,212,0000.22%
FRANKLIN STREET ADVISORS INC /NC 93,000$984,0000.20%
THB ASSET MANAGEMENT 301,529$3,190,0000.19%
TPG Group Holdings (SBS) Advisors, Inc. 1,162,269$12,297,0000.13%
View complete list of BIOCRYST PHARMACEUTICALS INC shareholders